Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
m (Meetings)
m (Meetings)
Line 6: Line 6:
  
 
'''Recent Call Summaries:'''
 
'''Recent Call Summaries:'''
 +
 +
*[[Media: 2018 10 08 QIBA CT Angiography_FINAL.pdf | October 8, 2018]]
 
*[[Media: 2018 09 24 QIBA CT Angiography_FINAL.pdf | September 24, 2018]]
 
*[[Media: 2018 09 24 QIBA CT Angiography_FINAL.pdf | September 24, 2018]]
 
*[[Media: 2018 08 27 QIBA CT Angiography_FINAL.pdf | August 27, 2018]]
 
*[[Media: 2018 08 27 QIBA CT Angiography_FINAL.pdf | August 27, 2018]]

Revision as of 21:34, 12 October 2018

Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT Secretary: Julie Lisiecki

Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Groundwork Projects

Reference Materials

Conformance Materials